| Nome |
# |
|
Il nefrologo nel trattamento dell’iperammoniemia da
disordini del ciclo dell’urea, file e268a72e-032b-4c8f-e053-1705fe0a812c
|
10.055
|
|
Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature, file e268a72e-0445-4c8f-e053-1705fe0a812c
|
1.163
|
|
Parapelvic Cysts: An Imaging Marker of Kidney Disease Potentially Leading to the Diagnosis of Treatable Rare Genetic Disorders? A Narrative Review of the Literature, file ccdf3a78-df0c-42d3-9f2b-cca058069f6d
|
1.068
|
|
Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease, file e268a72d-fa4e-4c8f-e053-1705fe0a812c
|
562
|
|
Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature, file a56d5833-4dec-49d6-baf0-6dde470768a1
|
223
|
|
Therapeutic advances in ADPKD: the future awaits, file e268a733-6268-4c8f-e053-1705fe0a812c
|
223
|
|
Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature., file e268a72e-0352-4c8f-e053-1705fe0a812c
|
192
|
|
Effect of a Short-Course Treatment with Synbiotics on Plasma p-Cresol Concentration in Kidney Transplant Recipients., file e268a72e-d13f-4c8f-e053-1705fe0a812c
|
155
|
|
Fabry's disease: a comparison of the effectiveness of two different enzyme replacement therapies, file e268a72e-0442-4c8f-e053-1705fe0a812c
|
149
|
|
Pathogenesis of Acute Renal Failure Induced by Iodinated Radiographic Contrast Media, file e268a72e-0840-4c8f-e053-1705fe0a812c
|
125
|
|
Renal denervation in ADPKD: an exceptional case, file e268a72d-fc09-4c8f-e053-1705fe0a812c
|
88
|
|
Pituitary function and morphology in Fabry disease., file e268a72d-fb96-4c8f-e053-1705fe0a812c
|
68
|
|
Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial, file e268a72e-4de9-4c8f-e053-1705fe0a812c
|
67
|
|
Genetic variants associated with gastrointestinal symptoms in Fabry disease., file e268a72d-f790-4c8f-e053-1705fe0a812c
|
46
|
|
6-tips diet: a simplified dietary approach in patients with chronic renal disease. A clinical randomized trial, file e268a72d-f9c2-4c8f-e053-1705fe0a812c
|
46
|
|
Hybrid positron emission tomography-magnetic resonance imaging for assessing different stages of cardiac impairment in patients with Anderson-Fabry disease: AFFINITY study group, file e268a732-dfc2-4c8f-e053-1705fe0a812c
|
43
|
|
Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease., file e268a72c-c7e8-4c8f-e053-1705fe0a812c
|
40
|
|
Arterial aneurysms: autosomal dominant polycystic kidney disease, Marfan syndrome or both?, file e268a72c-d5f7-4c8f-e053-1705fe0a812c
|
39
|
|
Treatment with Agalsidase Alfa during Pregnancy in a Heterozygous Female with Fabry Disease, file e268a72d-f4e9-4c8f-e053-1705fe0a812c
|
39
|
|
The potential use of biomarkers in predicting contrast-induced acute kidney injury., file e268a72d-ff4b-4c8f-e053-1705fe0a812c
|
35
|
|
Methylome Profiling in Fabry Disease in Clinical Practice: A Proof of Concept, file b1c7a5fc-5694-4bcb-bf43-afed9bf7e719
|
30
|
|
Cerebrovascular and Brain Abnormalities In Autosomal-Dominant Polycystic Kidney Disease: Role Of 3d Time-of-Flight Magnetic Resonance Angiography, file e268a72d-ff5c-4c8f-e053-1705fe0a812c
|
26
|
|
Terapia enzimatica sostitutiva nella malattia di Fabry: cosa abbiamo imparato dallo switch?, file e268a72d-f5bc-4c8f-e053-1705fe0a812c
|
23
|
|
Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease, file e268a732-8047-4c8f-e053-1705fe0a812c
|
22
|
|
Fanconi syndrome with lysinuric protein intolerance, file e268a72d-fc06-4c8f-e053-1705fe0a812c
|
20
|
|
SWITCH TO AGALSIDASE ALFA AFTER THE SHORTAGE OF AGALSIDASE BETA IN FABRY DISEASE: A SYSTEMATIC REVIEW WITH METANALYSIS OF THE LITERATURE, file e268a72d-f797-4c8f-e053-1705fe0a812c
|
18
|
|
Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis., file e268a731-14e7-4c8f-e053-1705fe0a812c
|
16
|
|
Reduced intracranial volume in Fabry Disease: Evidence of abnormal neurodevelopment?, file e268a72f-fc5d-4c8f-e053-1705fe0a812c
|
15
|
|
6-tips diet: a simplified dietary approach in patients with chronic renal disease. A clinical randomized trial, file e268a730-64f4-4c8f-e053-1705fe0a812c
|
14
|
|
Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome, file e268a72d-fc13-4c8f-e053-1705fe0a812c
|
13
|
|
Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer, file e268a732-d7e3-4c8f-e053-1705fe0a812c
|
13
|
|
Multimodality imaging approach to Fabry cardiomyopathy: Any role for nuclear cardiology?, file e268a733-a76b-4c8f-e053-1705fe0a812c
|
13
|
|
Molecular Mechanisms of Renal Cellular Nephrotoxicity due to Radiocontrast Media, file e268a72d-1ed8-4c8f-e053-1705fe0a812c
|
12
|
|
Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?, file e268a72d-1f28-4c8f-e053-1705fe0a812c
|
12
|
|
Optical Coherence Tomography Angiography Findings in Fabry Disease, file e268a731-3de3-4c8f-e053-1705fe0a812c
|
12
|
|
Atrial septum aneurysm: an unusual manifestation in ADPKD?, file e268a72d-fb89-4c8f-e053-1705fe0a812c
|
10
|
|
Catheter-Based Renal Denervation in ADPKD: Just for Pain Control?, file e268a72d-e454-4c8f-e053-1705fe0a812c
|
8
|
|
Nutritional treatment in chronic kidney disease: the concept of nephroprotection., file e268a72e-1d7c-4c8f-e053-1705fe0a812c
|
8
|
|
Early Cardiac Involvement Affects Left Ventricular Longitudinal Function in Females Carrying α-Galactosidase A Mutation: Role of Hybrid Positron Emission Tomography and Magnetic Resonance Imaging and Speckle-Tracking Echocardiography, file e268a732-7c3c-4c8f-e053-1705fe0a812c
|
8
|
|
Molecular and clinical studies in five index cases with novel mutations in the GLA gene., file e268a730-6157-4c8f-e053-1705fe0a812c
|
7
|
|
The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials, file e268a733-466d-4c8f-e053-1705fe0a812c
|
7
|
|
Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial, file e268a730-5e32-4c8f-e053-1705fe0a812c
|
6
|
|
Cerebrovascular and Brain Abnormalities In Autosomal-Dominant Polycystic Kidney Disease: Role Of 3d Time-of-Flight Magnetic Resonance Angiography, file e268a730-63a6-4c8f-e053-1705fe0a812c
|
6
|
|
Immunosuppression and multiple primary malignancies in kidney transplanted patients. A single-institute study, file e268a732-bafd-4c8f-e053-1705fe0a812c
|
6
|
|
Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol, file e268a732-f271-4c8f-e053-1705fe0a812c
|
6
|
|
Cardiovascular magnetic resonance native T1 mapping in Anderson-Fabry disease: a systematic review and meta-analysis, file e268a733-a0e8-4c8f-e053-1705fe0a812c
|
6
|
|
Acute kidney injury by radiographic contrast media: pathogenesis and prevention., file e268a72e-0d08-4c8f-e053-1705fe0a812c
|
5
|
|
The potential use of biomarkers in predicting contrast-induced acute kidney injury., file e268a730-6716-4c8f-e053-1705fe0a812c
|
4
|
|
Mutations in the GLA gene and LysoGb3: Is it really Anderson-Fabry disease?, file e268a731-6cf5-4c8f-e053-1705fe0a812c
|
4
|
|
Molecular and clinical studies in five index cases with novel mutations in the GLA gene., file e268a72d-f90b-4c8f-e053-1705fe0a812c
|
3
|
|
Nutritional treatment in chronic kidney disease: the concept of nephroprotection., file e268a730-66b0-4c8f-e053-1705fe0a812c
|
3
|
|
Hypoxia-Inducible Factor Stabilizers in End Stage Kidney Disease: “Can the Promise Be Kept?”, file e268a733-3f42-4c8f-e053-1705fe0a812c
|
3
|
|
Experimental evidence and clinical implications of Warburg effect in the skeletal muscle of Fabry disease, file 21c2e4d4-f97b-4cb1-a4e5-799558da94a3
|
2
|
|
Polycystic horseshoe kidney., file e268a72c-d54a-4c8f-e053-1705fe0a812c
|
2
|
|
Late diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease., file e268a730-6715-4c8f-e053-1705fe0a812c
|
2
|
|
Role of serial cardiac 18F-FDG PET-MRI in Anderson-Fabry disease: a pilot study, file e268a733-1a07-4c8f-e053-1705fe0a812c
|
2
|
|
Microstructural damage of the cortico-striatal and thalamo-cortical fibers in Fabry disease: a diffusion MRI tractometry study, file 1d589c4f-2c8e-4caf-b66d-e8eac02fa544
|
1
|
|
Advanced CMR Techniques in Anderson-Fabry Disease: State of the Art, file 5b8c3581-d72e-40d3-9cb6-210b37136be8
|
1
|
|
Ultra-deep dna methylation analysis of x-linked genes: Gla and ar as model genes [*De Riso G., Cuomo M co-primi autori], file 7684babb-9d87-4d50-beaa-7e979343bf59
|
1
|
|
Randomized Controlled Trials on Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease Stages 3-5: Are They Robust? A Fragility Index Analysis, file b811a5e8-335b-4e8b-be16-abe66ffcdc2a
|
1
|
|
Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis, file e268a72e-b71e-4c8f-e053-1705fe0a812c
|
1
|
|
Parapelvic cysts, a distinguishing feature of renal Fabry Disease., file e268a72f-f91f-4c8f-e053-1705fe0a812c
|
1
|
|
Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease, file e268a732-8aaa-4c8f-e053-1705fe0a812c
|
1
|
|
RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study, file fc98b5de-b6ac-4285-b8cb-8ac17f5187f4
|
1
|
| Totale |
14.801 |